Amgen's stock surged 5.30% during intraday trading on Wednesday, reflecting a significant positive movement in the market.

The sharp rise follows the company's release of fourth-quarter financial results that exceeded analyst expectations, with adjusted earnings per share of $5.29 beating the estimate of $4.73. Revenue for the quarter reached $9.9 billion, surpassing the anticipated $9.5 billion. Furthermore, Amgen provided an optimistic profit forecast for 2026, projecting adjusted earnings per share between $21.60 and $23, above the average analyst estimate of $22.09.

Analysts have reacted positively to the report, with several brokerages raising their price targets on the stock. The strong performance was attributed to robust sales from key products like Prolia, Evenity, Repatha, and Vectibix. Additionally, investor sentiment is bolstered by optimism surrounding Amgen's pipeline, particularly the potential of its experimental weight-loss drug MariTide, which is seen as a long-term growth driver.